Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Small Cell Lung Cancer Resource Center

Advertisement

Trending From ACCC
Barriers to Treating Patients With Small Cell Lung Cancer: Findings from a Survey of Patients and Providers
06/05/2023
American Association of Community Cancer Centers
This column describes the findings from 2022 Association of Community Cancer Centers (ACCC) surveys with patients and providers that aimed to define the barriers that patients with small cell lung cancer face. The surveys gathered real-world...
This column describes the findings from 2022 Association of Community Cancer Centers (ACCC) surveys with patients and providers that aimed to define the barriers that patients with small cell lung cancer face. The surveys gathered real-world...
This column describes the...
06/05/2023
Journal of Clinical Pathways
Conference Coverage
Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/13/2022

Katie Herman

Katie Herman
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues...
12/13/2022
Journal of Clinical Pathways
Jerome Goldschmidt, MD
Videos
Health Care Resource Utilization, Costs, and Treatment Patterns Among Patients With Extensive-Stage SCLC Treated in the Community Oncology Setting
03/25/2022
Jerome Goldschmidt, MD, discusses recent study findings that suggest patients with small cell lung cancer receiving myelosuppressive chemotherapy with or without atezolizumab may experience more clinical burdens and more financial toxicity.
Jerome Goldschmidt, MD, discusses recent study findings that suggest patients with small cell lung cancer receiving myelosuppressive chemotherapy with or without atezolizumab may experience more clinical burdens and more financial toxicity.
Jerome Goldschmidt, MD,...
03/25/2022
Journal of Clinical Pathways
News
Durvalumab Added to Etoposide Plus Platinum is Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
12/22/2021

Janelle Bradley

Janelle Bradley
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide...
12/22/2021
Journal of Clinical Pathways
News
Anlotinib Safe, Effective as Third- or Later-line Treatment for Refractory SCLC
12/03/2021

Marta Rybczynski

Marta Rybczynski
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study...
12/03/2021
Journal of Clinical Pathways
Quiz
Quiz: Evolution of Diagnosis and Treatment of SCLC
11/18/2021
True or False: The increase in the use of carboplatin and brain imaging at diagnosis in patients with SCLC from 2000 to 2021 has not demonstrated a significant impact on survival.
True or False: The increase in the use of carboplatin and brain imaging at diagnosis in patients with SCLC from 2000 to 2021 has not demonstrated a significant impact on survival.
True or False: The increase in...
11/18/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Third-Line Nivolumab for SCLC
11/15/2021
True or False: Nivolumab monotherapy is not considered cost-effective compared to commonly prescribed third-line treatment for the treatment of small cell lung cancer.
True or False: Nivolumab monotherapy is not considered cost-effective compared to commonly prescribed third-line treatment for the treatment of small cell lung cancer.
True or False: Nivolumab...
11/15/2021
Journal of Clinical Pathways
News
Evolution of Diagnosis and Treatment of SCLC Over the Last 20 Years
10/22/2021

Marta Rybczynski

Marta Rybczynski
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that...
10/22/2021
Journal of Clinical Pathways
David Tsui, MD
Videos
Real-World Adoption and Outcomes of Atezolizumab Plus Carboplatin and Etoposide for Extensive-Stage SCLC
10/04/2021
David Chun Cheong Tsui, MD, discusses results from a real-world study exploring the adoption and early clinical outcomes of atezolizumab plus carboplatin and etoposide in patients with extensive-stage SCLC.
David Chun Cheong Tsui, MD, discusses results from a real-world study exploring the adoption and early clinical outcomes of atezolizumab plus carboplatin and etoposide in patients with extensive-stage SCLC.
David Chun Cheong Tsui, MD,...
10/04/2021
Journal of Clinical Pathways
News
Third-Line Nivolumab Cost-Effective Compared to Topotecan for SCLC
09/07/2021
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that...
09/07/2021
Journal of Clinical Pathways
News
Durvalumab Plus Chemotherapy Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
09/01/2021
Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.
Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.
Study findings suggest...
09/01/2021
Journal of Clinical Pathways

Advertisement

News Articles

Conference Coverage
Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/13/2022

Katie Herman

Katie Herman
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues...
12/13/2022
Journal of Clinical Pathways
News
Durvalumab Added to Etoposide Plus Platinum is Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
12/22/2021

Janelle Bradley

Janelle Bradley
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide...
12/22/2021
Journal of Clinical Pathways
News
Anlotinib Safe, Effective as Third- or Later-line Treatment for Refractory SCLC
12/03/2021

Marta Rybczynski

Marta Rybczynski
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study...
12/03/2021
Journal of Clinical Pathways
News
Evolution of Diagnosis and Treatment of SCLC Over the Last 20 Years
10/22/2021

Marta Rybczynski

Marta Rybczynski
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that changes in the clinical management of patients with SCLC over the last 20 years have not had a significant impact on survival.
Study findings suggest that...
10/22/2021
Journal of Clinical Pathways
News
Third-Line Nivolumab Cost-Effective Compared to Topotecan for SCLC
09/07/2021
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that nivolumab monotherapy is a more cost-effective treatment option compared to topotecan for the third-line treatment of SCLC.
A recent study revealed that...
09/07/2021
Journal of Clinical Pathways
News
Durvalumab Plus Chemotherapy Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
09/01/2021
Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.
Study findings suggest durvalumab plus chemotherapy is not a cost-effective first-line treatment option for patients with extensive-stage SCLC.
Study findings suggest...
09/01/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of First-Line Chemo-Immunotherapy for Extensive-Stage SCLC
08/05/2021
Study findings suggest atezolizumab plus etoposide and platinum chemotherapy is superior to durvalumab plus etoposide and platinum chemotherapy for treating extensive-stage SCLC, though neither strategy was cost-effective compared to...
Study findings suggest atezolizumab plus etoposide and platinum chemotherapy is superior to durvalumab plus etoposide and platinum chemotherapy for treating extensive-stage SCLC, though neither strategy was cost-effective compared to...
Study findings suggest...
08/05/2021
Journal of Clinical Pathways
News
Nivolumab vs Standard of Care for Third-Line Treatment of SCLC
08/04/2021
Study findings show third-line treatment with nivolumab was more effective than standard of care therapy for patients with SCLC in the United States.
Study findings show third-line treatment with nivolumab was more effective than standard of care therapy for patients with SCLC in the United States.
Study findings show third-line...
08/04/2021
Journal of Clinical Pathways
News
Real-World Treatment Patterns and Outcomes Among Patients With SCLC
07/22/2021
A recent systematic review on real-world treatment patterns and outcomes in patients with SCLC found that studies conducted over the last 20 years have failed to report on the impact of recently approved immune-oncology therapies.
A recent systematic review on real-world treatment patterns and outcomes in patients with SCLC found that studies conducted over the last 20 years have failed to report on the impact of recently approved immune-oncology therapies.
A recent systematic review on...
07/22/2021
Journal of Clinical Pathways
News
First-Line Atezolizumab Plus Chemotherapy Not Cost-Effective for SCLC
06/23/2021
A recent cost-effective analysis of first-line treatments for extensive-stage SCLC suggests that atezolizumab plus chemotherapy is not cost-effective in the United States.
A recent cost-effective analysis of first-line treatments for extensive-stage SCLC suggests that atezolizumab plus chemotherapy is not cost-effective in the United States.
A recent cost-effective analysis...
06/23/2021
Journal of Clinical Pathways
News
Examining Treatment Delay Trends in Patients With Lung Cancer
07/24/2024
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a disturbing trend of increasing delays in lung cancer treatment initiation, surpassing national guidelines and prompting a call for further investigation into potential causes.
A study in Missouri uncovers a...
07/24/2024
Journal of Clinical Pathways
Laura Bray
Videos
Advocacy to Reduce the Impact of Drug Shortages on Cancer Care
07/23/2024
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her experience as a patient advocate with Angels of Change and the key drivers impacting drug shortages.
Laura Bray, MBA, talks about her...
07/23/2024
Journal of Clinical Pathways
News
First-Line Amivantamab Plus Lazertinib Superior to Osimertinib Among Patients With Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Results from the phase 3...
07/18/2024
Oncology
Steve Kalloger, MSc
Videos
Trends in Therapeutic Utilization Among Patients With CLL: Results From the Lymphoma Coalition’s 2022 Global Patient Survey Presented at ASCO 2024
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Steve Kalloger, MSc, discusses...
07/18/2024
Journal of Clinical Pathways
News
Perioperative Nivolumab Prolonged Event-Free Survival Compared to Perioperative Chemotherapy Among Patients With Resectable Non-Small Cell Lung Cancer
07/15/2024
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3 CheckMate 77T trial demonstrated that perioperative nivolumab prolonged event-free survival compared to perioperative chemotherapy among patients with resectable non-small cell lung cancer.
Results from the phase 3...
07/15/2024
Oncology
Stephen Colvill, MBA
Conference Coverage
How Collaboration Among Health Care Stakeholders Can Help Mitigate Drug Shortages
07/08/2024
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses how collaboration, proactive strategies, and technology can help prevent drug shortages.
Stephen Colvill, MBA, discusses...
07/08/2024
Journal of Clinical Pathways
News
Improving Care for Patients With Cancer Through Early Goal of Care Discussions
07/03/2024
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic documentation of physician-led goals of care discussions in patients with cancer can lead to improved care integration across health care settings, ensuring comprehensive and individualized quality care for patients...
Standardizing electronic...
07/03/2024
Journal of Clinical Pathways
Conference Coverage
The Association Between High Deductible Health Plans and Cancer Survival
07/02/2024
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented at ASCO 2024, researchers found that high deductible health plans are associated with worse survival in cancer survivors.
According to findings presented...
07/02/2024
Journal of Clinical Pathways
News
Impact of Care Delays on Health Care Resource Utilization in Patients With Early-Stage Lung Cancer
06/26/2024

Brandon Twyford

Brandon Twyford
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on the real-world ramifications of delayed surgical intervention in early-stage non–small cell lung cancer, highlighting the complex relationship between timing of surgery, patient outcomes, and health care...
Researchers conducted a study on...
06/26/2024
Journal of Clinical Pathways
Moritz Furstenau, MD
Conference Coverage
Efficacy and ctDNA Analysis of MRD-Guided Acalabrutinib, Venetoclax, and Obinutuzumab for Patients With R/R CLL
06/26/2024

Featuring Moritz Furstenau, MD

Featuring Moritz Furstenau, MD ...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting, Moritz Furstenau, MD, presented a follow-up analysis of the CLL2-Baag trial on the efficacy and ctDNA analysis of acalabrutinib, venetoclax, and obinutuzumab combination therapy after optional debulking with...
At the 65th ASH Annual Meeting,...
06/26/2024
Oncology

Interactive Features

Quiz
Quiz: Evolution of Diagnosis and Treatment of SCLC
11/18/2021
True or False: The increase in the use of carboplatin and brain imaging at diagnosis in patients with SCLC from 2000 to 2021 has not demonstrated a significant impact on survival.
True or False: The increase in the use of carboplatin and brain imaging at diagnosis in patients with SCLC from 2000 to 2021 has not demonstrated a significant impact on survival.
True or False: The increase in...
11/18/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Third-Line Nivolumab for SCLC
11/15/2021
True or False: Nivolumab monotherapy is not considered cost-effective compared to commonly prescribed third-line treatment for the treatment of small cell lung cancer.
True or False: Nivolumab monotherapy is not considered cost-effective compared to commonly prescribed third-line treatment for the treatment of small cell lung cancer.
True or False: Nivolumab...
11/15/2021
Journal of Clinical Pathways
Quiz
Quiz: Third-Line Treatment for SCLC
08/30/2021
True or False: Nivolumab is less effective than standard of care for the third-line treatment of SCLC.
True or False: Nivolumab is less effective than standard of care for the third-line treatment of SCLC.
True or False: Nivolumab is less...
08/30/2021
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Prophylactic Cranial Irradiation vs MRI Surveillance for SCLC
07/15/2021
True or False: Prophylactic cranial irradiation is cost-effective compared with MRI surveillance for extensive-stage small cell lung cancer.
True or False: Prophylactic cranial irradiation is cost-effective compared with MRI surveillance for extensive-stage small cell lung cancer.
True or False: Prophylactic...
07/15/2021
Journal of Clinical Pathways
Test Your Knowledge
Quiz: Risk for Brain Metastases Higher With Twice-Daily Radiotherapy for SCLC?
08/01/2019
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with SCLC undergoing radiotherapy twice daily are more likely to have brain metastases after prophylactic cranial irradiation than those given radiotherapy once daily.
True or false: Patients with...
08/01/2019
Oncology
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

JCP May/June 2024 Issue

Current Issue

June 2024
Volume 10
Issue 3
Current Issue
Issue Archive

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Winston Wong, PharmD
Gordon Kuntz
Robin T Zon, MD, FACP, FASCO
2021 Care Pathways Working Group
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
Special Report
Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma
01/14/2021
01/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Subscribe

Journal of Clinical Pathways Newsletter

Advertisement

Advertisement

Advertisement

Recent Stories

Trending From ACCC
Barriers to Treating Patients With Small Cell Lung Cancer: Findings from a Survey of Patients and Providers
06/05/2023
American Association of Community Cancer Centers
This column describes the findings from 2022 Association of Community Cancer Centers (ACCC) surveys with patients and providers that aimed to define the barriers that patients with small cell lung cancer face. The surveys gathered real-world...
This column describes the findings from 2022 Association of Community Cancer Centers (ACCC) surveys with patients and providers that aimed to define the barriers that patients with small cell lung cancer face. The surveys gathered real-world...
This column describes the...
06/05/2023
Journal of Clinical Pathways
Conference Coverage
Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/13/2022

Katie Herman

Katie Herman
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues...
12/13/2022
Journal of Clinical Pathways
Jerome Goldschmidt, MD
Videos
Health Care Resource Utilization, Costs, and Treatment Patterns Among Patients With Extensive-Stage SCLC Treated in the Community Oncology Setting
03/25/2022
Jerome Goldschmidt, MD, discusses recent study findings that suggest patients with small cell lung cancer receiving myelosuppressive chemotherapy with or without atezolizumab may experience more clinical burdens and more financial toxicity.
Jerome Goldschmidt, MD, discusses recent study findings that suggest patients with small cell lung cancer receiving myelosuppressive chemotherapy with or without atezolizumab may experience more clinical burdens and more financial toxicity.
Jerome Goldschmidt, MD,...
03/25/2022
Journal of Clinical Pathways
News
Durvalumab Added to Etoposide Plus Platinum is Not Cost-Effective for First-Line Treatment of Extensive-Stage SCLC
12/22/2021

Janelle Bradley

Janelle Bradley
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide and platinum is not cost-effective compared with etoposide and platinum alone for patients with newly diagnosed extensive-stage SCLC from a US payer perspective.
Adding durvalumab to etoposide...
12/22/2021
Journal of Clinical Pathways
News
Anlotinib Safe, Effective as Third- or Later-line Treatment for Refractory SCLC
12/03/2021

Marta Rybczynski

Marta Rybczynski
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study show anlotinib is beneficial for patients with refractory SCLC as third- or further-line treatment with manageable adverse effects.
Results from a real-world study...
12/03/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement